miR-613 suppresses renal cell carcinoma proliferation, invasion and migration by regulating the AXL/AKT pathway

Wanli Duan1, Siyuan Pan2, Yuyao Zhai3

  • 1Department of Urology, Shaanxi Provincial People's Hospital, Xi'an 710068, P.R. China.

Insights

MicroRNA-613 (miR-613) is downregulated in renal cell carcinoma (RCC). Upregulating miR-613 inhibits RCC proliferation and metastasis by targeting AXL and the PI3K/AKT pathway.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) show potential in cancer treatment.
  • The specific role of miR-613 in renal cell carcinoma (RCC) remains largely unknown.
  • Understanding miR-613's function is crucial for developing novel RCC therapies.

Purpose of the Study:

  • To investigate the influence of miR-613 on RCC cell proliferation, invasion, and migration.
  • To elucidate the underlying molecular mechanism of miR-613 in RCC.
  • To determine the relationship between miR-613 and its potential target, AXL.

Main Methods:

  • Quantification of miR-613 expression in RCC tissues and cell lines (786-O, ACHN).
  • Bioinformatic analysis and literature review to identify miR-613 targets.
  • Phenotype, mechanism, rescue assays (AXL overexpression), and in vivo experiments.

Main Results:

  • miR-613 expression was found to be significantly downregulated in RCC tissues and cells.
  • AXL was identified as a direct target of miR-613 in RCC.
  • Overexpression of miR-613 suppressed RCC proliferation, invasion, and migration by reducing AXL levels and inhibiting the PI3K/AKT signaling pathway.

Conclusions:

  • miR-613 acts as a tumor suppressor in renal cell carcinoma.
  • The miR-613/AXL/PI3K/AKT axis represents a potential therapeutic target for RCC.
  • Restoring miR-613 levels may offer a new strategy for treating renal cell carcinoma.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K